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Abstract
Introduction: Although pre-exposure prophylaxis (PrEP.) is an efficacious HIV prevention strategy, its preventive benefit has
not been shown among young women in sub-Saharan Africa, likely due to non-adherence. Adherence may be improved with
the use of injectable long-acting PrEP methods currently being developed. We hypothesize that providing long-acting PrEP to
women using injectable contraceptives, the most frequently used contraceptive method in South Africa, could improve adher-
ence to PrEP, result in a reduction of new HIV infections, and be a relatively easy-to-reach target population. In this modelling
study, we assessed the epidemiological impact and cost-effectiveness of providing long-acting PrEP to injectable contraceptive
users in Limpopo, South Africa.
Methods: We developed a deterministic mathematical model calibrated to the HIV epidemic in Limpopo. Long-acting PrEP
was provided to 50% of HIV negative injectable contraceptive users in 2018 and scaled-up over two years. We estimated the
number of HIV infections that could be averted by 2030 and the drug price of long-acting PrEP for which this intervention
would be cost-effective over a time horizon of 40 years, from a healthcare payer perspective. In the base-case scenario we
assumed long-acting PrEP is 75% effective in preventing HIV infections and 85% of infected individuals are on antiretroviral
drug therapy (ART) by 2030. In sensitivity analyses we adjusted PrEP effectiveness and ART coverage. Costs between $519
and $1119 per disability-adjusted life-year (DALY) averted were considered potentially cost-effective, and <$519 as cost-
effective.
Results: Without long-acting injectable PrEP, 224,000 (interquartile range 176,000 to 271,000) new infections will occur by
2030; use of long-acting injectable PrEP could prevent 21,000 (17,000 to 26,000) or 9.8% (8.9% to 10.6%) new HIV infections
by 2030 (including 6000 (4000 to 7000) in men). Long-acting PrEP would prevent 34,000 (29,000 to 39,000) or 12,000
(8000 to 15,000) at 75% and 95% ART coverage by 2030 respectively. To be considered potentially cost-effective the annual
long-acting PrEP drug price should be <$16, and/or ART coverage remains at <85% in 2030.
Conclusions: Providing long-acting PrEP to injectable contraceptive users in Limpopo is only potentially cost-effective when
long-acting PrEP drug prices are low. If low prices are not feasible, providing long-acting PrEP only to women at high risk of
HIV infection will become important.
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1 | INTRODUCTION
Women in South Africa have a disproportionate risk of HIV-in-
fection as illustrated by an incidence of 2.5% per year for
women aged 15 to 24 years, which is almost five times higher
than the incidence in men of the same age. Although this dif-
ference between men and women decreases at older ages,
the HIV incidence remains higher for women [1]. Therefore,
South African women might particularly benefit from HIV pre-
vention strategies.
Pre-exposure prophylaxis (PrEP) is an effective HIV preven-
tion strategy in high-risk populations with reported risk reduc-
tions of 44% to 86% for acquiring HIV infection [2]. However,
studies of daily oral PrEP in the general population of
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heterosexual African women have not shown similar efficacy
rates. An important reason is low adherence as suggested by
drug concentration studies [2–4].
In the past few years, injectable, long-acting forms of differ-
ent antiretroviral drugs have been developed that have the
potential for use as long-acting PrEP [5]; the first clinical trial
of injectable long-acting PrEP is ongoing [6]. A possible advan-
tage of injectable long-acting PrEP is that it can reduce the
low effectiveness of oral PrEP that is due to poor adherence.
Key user groups, including young African women, indicated a
preference for long-acting forms of PrEP compared to daily
intake [7–9]. Therefore if long-acting injectable PrEP were to
become available, there may also be greater uptake and
longer continuation of use than with daily oral PrEP.
An area that has shown success in long-acting drug delivery
modalities are injectable contraceptives which are used by 25% of
South African women aged 15 to 49 years [10]. While some
observational studies suggested progesterone-based injectables,
particularly depot medroxyprogesterone acetate (DMPA), might
increase the risk of HIV infection [11], a recent randomized con-
trolled study did not find an increased risk for HIV for women
using DMPA as compared to women using other contraceptive
methods [12]. However, women using injectable contraceptives
might still be an interesting target population for injectable forms
of long-acting PrEP. Combining long-acting PrEP with injectable
contraceptives in a single healthcare visit might improve uptake,
adherence and consequently, effectiveness, of long-acting PrEP
[8,13] and could protect sexually active women against both HIV
infection and unintended pregnancies. In addition, a combination
of both drugs could decrease overall costs.
Using data on contraceptive use, the HIV epidemic and the
ART programme in Limpopo, we aimed to model how many
HIV infections could be averted if injectable contraceptive
users started using long-acting PrEP. We also determined
the cost at which long-acting PrEP drugs would be cost-
effective. Limpopo was chosen because we had access to
high-quality data for this part of South Africa through the
Anova Health Institute.
2 | METHODS
2.1 | The model
We developed a mathematical HIV transmission model repre-
senting the general HIV epidemic in men and women aged 15
to 49 years old in Limpopo (Figure S1A,B). This compartmental
model stratifies disease progression into the acute stage, the
chronic stage (sub-divided in three stages based on CD4 cell
count: CD4 level >500, 350 to 500 and 200 to 350 cells/lL),
the AIDS stage (CD4 level <200 cells/lL), and in individuals
receiving antiretroviral treatment (ART). Each stage of infection
has a different duration, infectivity and rate at which infected
people start treatment. For example, since most individuals
using ART will be virally suppressed, the infectivity when using
ART is low (Table 1). We did not consider loss-to-follow-up
while using ART. Each stage of infection has a different duration,
infectivity and rate at which infected people start treatment.
Use of ART reduces the viral load and consequently the infectiv-
ity of individuals using ART. Therefore, in our model infectivity
when using ART was 87.3%–99.6% lower as compared to the
infectivity of individuals with chronic HIV who are not using
ART (Table 1). Women are also classified based on contracep-
tive method use: no contraception, DMPA or any other method
(including two monthly injectables). Women can start or stop
using injectable contraception or another contraceptive method
and can also switch between them. We assume that the use of
injectable contraceptives and non-injectable contraceptives
remains stable. In our model, the number of yearly sexual part-
nerships is equal for men and women (Table 1; Text S1). We
assume that the proportion of HIV infected individuals using
ART rises from about 66% in 2017 to about 85% in 2030, as
predicted by the Thembisa model [14].
The model was calibrated to the historic HIV epidemic in Lim-
popo (2010 to 2017) based on: population size, HIV prevalence
for men and women, the proportion of HIV positive individuals
receiving ART, and the use of injectable and other forms of con-
traceptives (see supplement). Using Monte Carlo filtering tech-
niques [23] we accepted 389 of the 250,000 simulations that
matched the HIV epidemic in Limpopo. All reported results are
the median and interquartile range (IQR) of the accepted simu-
lations. The data for this model came from the publicly available
Thembisa model and included data from the years 1985 to
2014 [14]. No additional data were collected and ethical
approval was therefore not required.
2.2 | Intervention
In Limpopo, about 325,000 HIV negative women aged 15 to
49 years old use injectable contraceptives and are therefore
an interesting target group for injectable long-acting PrEP
[10,14,24]. We assume 50% of this group will use long-acting
PrEP with an effectiveness of 75% [15–17]. Long-acting PrEP
was initiated in 2018 and scaled-up over two years. Women
receiving long-acting PrEP are tested for HIV infection every
three months, the assumed frequency of long-acting PrEP
injections (Table 1).
2.3 | Epidemiological impact
We estimated the number of HIV infections that could be
averted using different effectiveness levels of long-acting PrEP.
The time horizon to determine the epidemiological impact is ten
years after a two-year period of scale-up (2018 to 2030) In
addition, we assessed the impact of different ART coverage
levels on the number of new infections and the potential impact
of long-acting PrEP for these different ART scenarios on the
number of new infections for the same period.
2.4 | Cost-effectiveness
All individuals in our model were assigned a cost and disability-
adjusted life-year (DALY) based on the stage of HIV-infection
(Table S4). We take a healthcare payer perspective and include
costs for HIV testing, ART and long-acting PrEP. The cost of
drugs, laboratory testing, staff and overhead costs were
included (Table S5). We varied the drug price of long-acting
PrEP to determine at what price long-acting PrEP could be
cost-effective. We compared incremental costs and DALYs of
long-acting PrEP use by 50% of injectable contraceptive users,
to the scenario of no use of long-acting PrEP for different effec-
tiveness levels of long-acting PrEP. The incremental cost-effec-
tiveness ratios (ICERs) were assessed for a 40-year time
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horizon, an estimated lifespan between the average age at HIV
infection and the life expectancy in South Africa. Costs and
DALYs were discounted at 3% per year. We used the average
exchange rate of 2017 to convert South African Rand to US dol-
lars. We compared the median ICER of all accepted simulations
to the used country-level cost-effectiveness threshold for South
Table 1. Model parameters
Description Estimate or range Reference
Effectiveness long-acting PrEP 75% (50% to 100%) [15–17]
Average number of sexual partnerships per year after the year 2001a 0.53 to 0.97 Model calibration
Increased risk for women to acquire HIV compared to men 2.25 to 4.80 Model calibration
Disease stage infectivity: transmission probability
per partnership per year
[18]; Model calibration
Acute stage 0.28 to 0.68
Chronic stages 0.081 to 0.15
AIDS stage 0.28 to 0.62
On treatmentb 0.00031 to 0.019
Mortality rates per year [19]
Population 0.029
Acute HIV 0.102
Chronic HIV stage 0.102
AIDS stage 0.633
On treatment 0.029 Assumption
Disease stages duration [20,21]
Acute stage 10 to 16 weeks
Chronic stage CD4 >500 cells/lL 0.87 to 1 year
Chronic CD4 350 to 500 cells/lL 2.9 to 3.1 years
Chronic CD4 200 to 350 cells/lL 3.6 to 3.9 years
Rate of getting treatment per year since treatment
became available for particular HIV stagec
Model calibration
Acute HIV 0.00 to 0.099
Chronic HIV CD4 >500 cells/lL 0.052 to 0.27
Chronic HIV CD4 350 to 500 cells/lL 0.052 to 0.27
Chronic HIV CD4 200 to 350 cells/lL 0.22 to 0.69
AIDS 0.34 to 0.85
Rate of getting treatment using long-acting PrEP 75% after 3 months in acute and
chronic stages
100% after 3 months in
AIDS stage
Assumption
Contraceptive use in Limpopo (2018 to 2030)d [10]; Model calibration
Women using DMPA 10.9% (7.0 to 16.2)
Women using other contraceptives
• Of which are injectables
38.4% (26.1 to 47.3)
• 38.7% (28.0 to 43.2)
New 15 years old per year entering the model 112,000 to 122,000 Model calibration
Costse [22]
Yearly cost long-acting PrEP excluding drug cost ($) 66.91
Cost of testing negative for HIV per test ($) 4.22
Cost of testing positive for HIV per test ($) 6.22
Cost of antiretroviral treatment per year ($) 249.52
Cost discounting rate per year 3%
Exchange rate, South African Rand to USD over year 2017 13.86: 1
aSee Table S1 for sexual partnerships over time; bInfectivity when on treatment depicts an average infectivity of all individuals using anti-retroviral
treatment which includes both virally suppressed and non-suppressed individuals; cValues for baseline scenario where 85% of HIV-infected individ-
uals use antiretroviral therapy (ART) in 2030. Values used after 2017 to obtain different proportions of infected individuals using ART in the sen-
sitivity analysis are depicted in the supplement. Different treatment guidelines over time are taken into account, see supplement; dMedian with
minimum and maximum values of simulations in this period; eSee Table S5 for more details.
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Africa, in which ratios below $519 are cost-effective and ratio’s
between $519 and $1119 are potentially cost-effective [25]. In
addition, we determined scenarios for which at least 90% of our
simulations were cost-effective.
2.5 | Sensitivity analysis
We estimated the number of averted infections when the
absolute uptake of long-acting PrEP by HIV negative injectable
users is lower (25%) or higher (75%) than predicted, if ART
use by infected individuals increases to 75% or 95% in 2030
and if the effectiveness of long-acting PrEP would be lower
(50%) or higher (100%) as compared to the assumed 75%
effectiveness which is mostly based on animal studies [15–
17]. In addition, we did a one-way sensitivity analysis where
we compared the median ICER of our simulations to the used
cost-effectiveness thresholds in which we included ranges for
cost and DALY discounting (0% to 5%), the exchange rate
(minimum and maximum rate of 2017), costs of ART (25%),
the yearly drug cost of long-acting PrEP ($0 to $100), the
proportion of infected individuals using ART in 2030 (75% to
95%) and long-acting PrEP effectiveness (50% to 100%).
Lastly, we included a scenario where the non-drug-related
costs for long-acting PrEP decreased by 30%, since a combi-
nation of injectable contraceptives and long-acting PrEP in a
single healthcare visit might reduce the total non-drug-related
costs for both (Table S5A).
3 | RESULTS
Long-acting PrEP, with an effectiveness of 75%, could prevent
22,000 (IQR 18,000 to 27,000) or 9.8% (8.9% to 10.6%) of
new HIV infections in Limpopo between 2018 and 2030 (Fig-
ure 1) when provided to half of HIV negative injectable con-
traceptive users. Six thousand (IQR 4000 to 7000) of these
infections would be prevented in men showing that long-
acting PrEP is not only beneficial for women (Figure S3). The
number of infections potentially averted by long-acting PrEP
increases with long-acting PrEP effectiveness from 16,000
(IQR 13,000 to 20,000) or 7.5% (IQR 6.9% to 8.2%) to
26,000 (IQR 20,000 to 32,000) or 11.9% (IQR 10.9% to
12.9%) if the effectiveness increases from 50% to 100%
respectively. (Figure 1).
3.1 | Influence of the use of ART and long-acting
PrEP on the number of HIV infections
Figure 2 shows the impact of long-acting PrEP and the propor-
tion of HIV infected individuals using ART on the number of
new infections in the period 2018 to 2030. In our baseline sce-
nario where 85% of infected individuals will use ART by 2030
and without long-acting PrEP, 224,000 (IQR 176,000 to
271,000) new infections will occur. Compared to the scenario
where 85% of infected individuals will use ART in 2030, the
number of new infections will increase by 97,000 (IQR 87,000
to 109,000) additional infections if only 75% of HIV-infected
receive ART in 2030. Conversely, if 95% of infected individuals
will use ART by 2030, 75,000 (IQR 66,000 to 84,000) infections
will be prevented compared to the scenario where 85% of
infected individuals will use ART in 2030 due to the impact of
treatment as prevention. Long-acting PrEP will prevent more
infections if a lower proportion of HIV-infected individuals
receive ART: in our model, the number of averted infections by
long-acting PrEP ranges from 12,000 (IQR 8000 to 15,000) if
95% of infected individuals will use ART by 2030, to 34,000
(IQR 29,000 to 39,000) if 75% of infected individuals will use
ART by 2030. Figure S4 shows the impact of long-acting PrEP if
the uptake by injectable contraceptive users is 25% or 75%. The
number of infections averted by long-acting PrEP increases pro-
portional with an increase in the uptake.
3.2 | Cost-effectiveness
Figure 3 shows how the cost-effectiveness of long-acting PrEP
provided to injectable contraceptive users varies with chang-
ing effectiveness levels of PrEP and drug costs of long-acting
PrEP using the median ICER of our simulations. By 2030, if
85% of HIV-positive individuals are on ART and the effective-
ness of long-acting PrEP is 75%, we estimate that yearly drug
cost of long-acting PrEP should be $16 at most to be
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Figure 1. Short-term epidemiological impact of long-acting pre-ex-
posure prophylaxis (PrEP) on the HIV epidemic in Limpopo (2018
to 2030), assuming 50% of injectable contraceptives users use
long-acting PrEP. In the analysis, we assumed an effectiveness of
long-acting PrEP ranging between 50% and 100%. Depicted are the
median and interquartile ranges of all accepted simulations.
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Figure 2. Effects of the coverage with antiretroviral therapy (ART)
in the population and long-acting pre-exposure prophylaxis
(PrEP) provided to half of injectable contraceptive users in Limpopo
on the number of new HIV infections in the period 2018 to 2030.
Baseline scenario assumes no long-acting PrEP and 85% of infected
individuals using ART by 2030. Effects of lower (75%) and higher
(95%) ART coverage in 2030 are depicted as well as the effect of
long-acting PrEP for all three different ART scenarios. Depicted are
the median and interquartile ranges of all accepted simulations.
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considered potentially cost-effective (ICER $1113 IQR $829
to $1696) and will not be considered definitely cost-effective
even if long-acting PrEP drugs would be free of charge (Fig-
ure 3b). Figure S5 shows the cost-effectiveness results for
which at least 90% of our simulations have an ICER below the
cost-effectiveness threshold. If ART use would rise to 85% in
2030, even at a long-acting PrEP drug price of $0, less than
90% of all simulations are potentially cost-effective. This is
because the use of long-acting PrEP is also accompanied by
non-drug related costs (Table S5A). A budget impact analyses
for the total programme costs in the first one to five years,
assuming long-acting PrEP is 75% effective is provided in
Table S6. In a case where there is a slower rise in ART use
with 75% of infected individuals on ART by 2030, more infec-
tions will be averted by long-acting PrEP and the cost-effec-
tiveness increases (Figure 3a). However, if 95% of infected
individuals are using ART by 2030, long-acting PrEP will not
be (potentially) cost-effective (Figure 3c). Cost-effectiveness
results are comparable if 25% or 75% of injectable contracep-
tive users will use long-acting PrEP (data not shown).
3.3 | Sensitivity analysis
The cost per DALY averted of long-acting PrEP provided to
injectable contraceptive users is most sensitive to ART use
(Figure 4) and ranges from $652 to $6500/DALY for an ART
coverage of 75% or 95% in 2030 respectively. Other impor-
tant parameters affecting the cost-effectiveness of long-acting
PrEP are yearly DALY and costs discounting rates and yearly
long-acting PrEP drug cost; long-acting PrEP is not (poten-
tially) cost-effective for most scenarios.
4 | DISCUSSION
In this study, we investigated the impact and cost-effective-
ness of long-acting PrEP provided to HIV negative injectable
contraceptive users in Limpopo. Our model predicts that
22,000 or 9.8% of new infections could be prevented
between 2018 and 2030 if half of HIV negative injectable
contraceptive users (11% of women aged 15 to 49 years) use
long-acting PrEP. Long-acting PrEP drug price should cost $16
or less to be potentially cost-effective.
The cost-effectiveness results are highly sensitive to ART
coverage. If ART coverage increases, the preventative impact
and cost-effectiveness of long-acting PrEP decrease. However,
increasing ART use will prevent more infections compared to
increasing uptake of long-acting PrEP by injectable contracep-
tive users. Therefore, efforts should be made to identify HIV
infections in a timely manner, to increase ART use and to
retain infected individuals in care to make sure they are virally
suppressed, in line with the current WHO guidelines [26].
Long-acting PrEP may then also be most cost-effective sooner,
rather than later, while ART coverage remains relatively low
(66% in Limpopo in 2017) [14]. Long-acting PrEP provided
to injectable contraceptive users was not found to be cost-
saving, even at a long-acting PrEP drug price of $0. Addition-
ally, less than 90% of accepted simulations had an ICER below
the potentially cost-effectiveness threshold in our baseline
scenario, when long-acting PrEP drugs were free (Figure S5).
This is because long-acting PrEP use is also accompanied by
non-drug-related costs (Table S5A).
In this study, we show that providing injectable contraceptive
users with long-acting PrEP is only cost-effective when long-act-
ing drug prices are low or if the HIV incidence remains relatively
high. Yearly drug cost of oral PrEP for women in South Africa is
estimated to be about $61 per person [22]. However, when
newly developed, it is likely that drug prices for injectable long-
acting PrEP will even be higher. So, even though the long-acting
PrEP drug price is not known yet, a yearly drug costs <$16 per
person is not expected. If low prices are not feasible and ART
coverage increases as predicted, it will become important to
provide long-acting PrEP only to populations with higher inci-
dence rates. In that case, long-acting PrEP should be targeted
at women who are at high risk of HIV infection. In practice,
women using injectable contraceptives might have a higher HIV
risk compared to women in general, because they will be sexu-
ally active and might have fewer incentives to use condoms.
However, differences in risk behaviour between injectable con-
traceptive users and women not using injectable contraceptives
were not assessed in our model, since the extent of differences
in sexual risk behaviour are not known.
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Figure 3. Cost-effectiveness of providing half of HIV negative injectable contraceptive users in Limpopo with long-acting pre-exposure pro-
phylaxis (PrEP) if the proportion of HIV infected individuals using antiretroviral therapy (ART) (a) increases to 75% by 2030; (b) increases as
predicted to 85% by 2030; (c) increases to 95% by 2030. A time horizon of 40 years is used. Red represents scenarios not cost-effective (costs
over $1119/DALY), light green represents potentially cost-effective scenarios (cost between $519–$1119 per DALY) and dark green represents
cost-effective scenarios (cost <$519/DALY). Depicted are the median incremental cost-effectiveness ratios of all accepted simulations.cting PrEP
for all three different ART scenarios. Depicted are the median and interquartile ranges of all accepted simulations.
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We assumed that half of HIV negative injectable contra-
ceptive users will use long-acting PrEP and injectable contra-
ceptive use will remain stable. Data about the potential
uptake of PrEP by women differ widely and the uptake will
also be influenced by the effectiveness, safety, costs and side
effects of long-acting PrEP as well as implementation strate-
gies [8,13,27–29]. However, in populations using injectable
contraceptives, acceptability of injectable long-acting PrEP
will probably be high and this combination could increase the
use of both drugs [8,13]. If women who are using no or
other contraceptive methods switch to injectable contracep-
tives with long-acting PrEP, the number of infections poten-
tially averted by long-acting PrEP would increase. However, a
change in uptake of long-acting PrEP had no effect on the
cost-effectiveness. In practice, women not using injectable
contraceptives could also start long-acting PrEP when avail-
able. In our model, the risk for HIV is comparable for women
using injectable contraceptives and the general population of
women. Therefore, cost-effectiveness results would be com-
parable if women not using injectable contraceptives would
start long-acting PrEP.
Use of injectable contraceptives by sexually active women
in South Africa is highest for women aged 15 to 34 [10].
Therefore, providing long-acting PrEP to injectable contracep-
tive users may disproportionately contribute to HIV preven-
tion among younger women, who have a higher HIV incidence
[1]. As such, our results are likely an underestimate of the
total benefits of PrEP targeted to this population.
Combining long-acting PrEP with injectable contraceptives
in a single health care visit could not only increase uptake and
adherence for both drugs, but could also decrease overall
costs. This cost reduction would improve cost-effectiveness of
long-acting PrEP, as shown in our sensitivity analyses. A possi-
ble drawback of combining both drugs in a single healthcare
visit could be a mismatch in dosing regimens. Development of
long-acting PrEP with different available dosing regimens is
therefore desirable. However, if long-acting PrEP has to be
administered more frequently, long-acting PrEP costs will
increase. Additionally, uptake of long-acting PrEP might
increase if both injections could be combined in a single shot.
Effectiveness of most antiretroviral drugs and injectable
contraceptives is not affected when combined together [30].
However, we recommend to study interactions between long-
acting PrEP and injectable contraceptives more extensively as
well as other possible side effects. Side effects of long-acting
PrEP could decrease its cost-effectiveness. Recently, concerns
about safety during conception when using dolutegravir [31],
an analogue of cabotegravir which is currently investigated as
long-acting PrEP (6), have been raised. These concerns could
delay the development of long-acting PrEP suitable for women
of childbearing age. However, dolutegravir can be used by
women who are using effective contraceptives [31], like inject-
able contraceptive users.
Our model has several strengths. First, we accounted for
the population-level effect of PrEP, meaning PrEP is not only
beneficial for individuals using PrEP, but also for (future) part-
ners of protected individuals. Second, we take into account
the newest WHO guideline regarding ART and show how this
could impact the HIV epidemic as well as the potential impact
of long-acting PrEP. Lastly, we calibrated our model to the
Figure 4. One-way sensitivity analysis of the incremental cost-effectiveness of long-acting pre-exposure prophylaxis (PrEP) provided to half
of HIV negative injectable contraceptive users in Limpopo compared to no long-acting PrEP over 40 years. At baseline, the proportion of
infected individuals using antiretroviral therapy (ART) will rise as predicted to 85% in 2030, long-acting PrEP is 75% effective, long-acting
PrEP drug costs $50 per year and non-drug related costs for long-acting PrEP are $66.91. Bars show the change in cost-effectiveness if the
value of the corresponding parameter is replaced by the value in parentheses. Red represents scenarios not cost-effective (costs over
$1119/DALY), light green represents potentially cost-effective scenarios (cost between $519 and $1119 per DALY) and dark green repre-
sents cost-effective scenarios (cost <$519/DALY). Depicted are the median incremental cost-effectiveness ratios of all accepted simulations.
Baseline scenario cost $1657 per DALY. DALY, disability-adjusted life-year, LA-PrEP, long-acting pre-exposure prophylaxis.
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well-described HIV epidemic in Limpopo and accurate data
about the ART programme in this region.
Our model has several limitations. First, we do not consider
a possible increase in resistance against antiretroviral drugs
using long-acting PrEP. Previous modelling studies estimated
HIV drug resistance resulting from PrEP will probably be lim-
ited [32]. However, risk of resistance is probably higher for
long-acting PrEP since these formulations are associated with
prolonged suboptimal drug levels that could facilitate the
emergence of drug resistance [33]. An oral PrEP ‘tail’ may
therefore be required, where oral PrEP is taken for several
months after the discontinuation of injectable PrEP, and the
effectiveness and adherence to this “tail” are unknown. Sec-
ond, all individuals in our model have the same number of sex-
ual partnerships in each model simulation, and no stratification
by age was considered. Since long-acting PrEP targeted at
women with a higher HIV incidence improves its cost-effec-
tiveness, providing long-acting PrEP to young women and
other high-risk populations will improve cost-effectiveness of
long-acting PrEP. However, there is no reliable data about sex-
ual risk behaviour in the population for different age cate-
gories and by use of contraceptive method, and identifying
highly sexually active individuals is difficult. Lastly, the future
uptake of long-acting PrEP may be much lower than the 50%
we assumed in our base-case scenario. Reducing the coverage
of long-acting PrEP will, however, result in a comparable cost-
effectiveness ratio.
Other studies have modelled the effect of oral or injectable
PrEP provided to the general population [34–39] or to women
[36,40–42] in an African setting, where [42] especially mod-
elled cost-effectiveness of methods combining HIV and preg-
nancy prevention. However, model input parameters and
outcome measures often differ between studies, complicating
comparison. For example, most studies were performed before
the current WHO guidelines regarding start of ART became
effective and time horizons chosen range between 10 years
to a lifetime. Most studies show PrEP could be cost-effective
in an African setting when provided to individuals at high risk
of HIV. Quaife et al [42] shows different scenarios for pre-
venting pregnancies and HIV infections using multi-purpose
prevention technologies in South Africa. They show this would
only be cost-effective for women aged 16 to 24, but not for
women aged 25 to 49 because of higher incidence rates for
younger women. Contrary to our model, as Quaife et al used
a static model, they could not consider the secondary infec-
tions that can be prevented on a population level due to use
of PrEP. In line with our results, multiple studies show cost-
effectiveness of PrEP decreases rapidly if ART use increases
and more infections can be averted by increasing ART
compared to PrEP [35,36,38–40]. Lastly, when comparing the
different studies, it is important to note that South Africa
does not have a generally accepted cost-effectiveness
threshold. As a consequence, the particular threshold that is
used should be considered when comparing different cost-
effectiveness studies.
5 | CONCLUSIONS
In summary, long-acting injectable forms of PrEP are under
development and could improve continuation of PrEP and
reduce effectiveness problems due to low adherence, which
have been observed in randomized controlled trials studying
oral PrEP in African women [2–4]. Injectable contraceptive
users are an interesting target group if injectable long-acting
PrEP becomes available. This is one potential way to identify
sexually active women at risk of HIV that find injections toler-
able. The combination of both injections in a single healthcare
visit could decrease costs and improve uptake and adherence
for both drugs.
However, long-acting PrEP provided to injectable contracep-
tive users in Limpopo could only be potentially cost-effective
if drug prices of long-acting PrEP will be low and challenges
with increasing ART use by infected individuals remain. To
improve cost-effectiveness of long-acting PrEP, it is desirable
to identify and target subpopulations with high HIV incidences
who are therefore at highest risk of HIV infection.
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SUPPORTING INFORMATION
Additional information may be found under the Supporting
Information tab for this article.
Figure S1. Model structure. A, Men. B, Women.
Figure S2. The model is calibrated to (A) The population size
in Limpopo (B) Proportion HIV-infected individuals (15 to
49 years) using antiretroviral treatment (ART) in Limpopo (C)
HIV prevalence in men (15 to 49 years) in Limpopo and (D)
HIV prevalence in women (15 to 49 years) in Limpopo. The
HIV prevalence in men and women and the proportion of
HIV-infected individuals using ART are calibrated to data from
the Thembisa model which is based on historic data. Depicted
are the median (black line) with the minimum and maximum
values of all accepted simulations in orange.
Figure S3. Epidemiological impact of long-acting pre-exposure
prophylaxis (PrEP) with an effectiveness of 75% on the HIV epi-
demic in Limpopo, assuming 50% of injectable contraceptives
users use long-acting PrEP and 85% of infected individuals uses
antiretroviral therapy (ART) by 2030. Total prevented infections
and infections prevented separated by men and women are
depicted. Prevented infections in men are an indirect result of
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long-acting PrEP use by women. Depicted are the median and
interquartile ranges of all accepted simulations.
Figure S4. Effects of the coverage with antiretroviral therapy
[23] in the population and long-acting pre-exposure prophy-
laxis (PrEP) targeted to injectable contraceptive users in Lim-
popo on the number of new HIV infections in the period
2018 to 2030. Baseline scenario assumes no long-acting PrEP
and 85% of infected individuals using ART by 2030. Effects of
lower (75%) and higher (95%) ART coverage in 2030 are
depicted as well as the effect of long-acting PrEP for all three
different ART scenarios. (A) 25% of HIV-negative injectable
users use long-acting PrEP (B) 75% of HIV-negative injectable
users use long-acting PrEP. Depicted are the median and
interquartile ranges of all accepted simulations. LA-
PrEP = long-acting pre-exposure prophylaxis
Figure S5. Cost-effectiveness of providing half of HIV negative
injectable contraceptive users in Limpopo with long-acting pre-
exposure prophylaxis (PrEP.) if the proportion of HIV infected
individuals using antiretroviral therapy (ART) (a) increases to
75% by 2030; (b) increases as predicted to 85% by 2030; (c)
increases to 95% by 2030. A time horizon of 40 years is used.
Red represents scenarios not cost-effective (costs over $1119/
DALY), light green represents potentially cost-effective scenar-
ios (cost between $519–$1119 per DALY) and dark green rep-
resents cost-effective scenarios (cost <$519/DALY). To be
considered (potentially) cost-effective, at least 90% of accepted
simulations have an incremental cost-effectiveness ratio below
the (potentially) cost-effectiveness threshold.
Text S1. Full model description and equations
Table S1. Number of sexual partnerships per year for
different periods in time
Table S2. A, Calibrated variables for the use of different con-
traceptive methods in the period before scale-up of long-act-
ing pre-exposure prophylaxis (PrEP). B, Variables after scale-
up period of long-acting pre-exposure prophylaxis (PrEP).
Values are adapted to obtain calibrated proportions of inject-
able contraceptive users on long-acting PrEP
Table S3. Range of values used for rates of getting treatment
after 2017. The rate of starting treatment before 2018 will
result in an overall proportion of 85% of HIV infected individ-
uals that will be using treatment in 2030. The HIV treatment
rates in 2018 and after were varied equally for all disease
stages to obtain 75% or 95% of HIV-infected individuals using
ART in 2030
Table S4. Assumed disability weightings for DALYs
Table S5. A, Costs for HIV testing, antiretroviral treatment
and long-acting pre-exposure prophylaxis (PrEP) in Limpopo
[15]. B, Overview used costs
Table S6. Variables used to calibrate and accept simulations
using Monte Carlo filtering techniques. 348 simulations were
accepted from 490,000 total simulations run
Table S7. Budget impact of providing half of HIV negative
injectable contraceptive users with long-acting PrEP, assuming
our baseline scenario with 85% ART coverage in 2030 and
long-acting PrEP effectiveness of 75%. Program costs are
depicted in million dollars. Drug costs of long-acting PrEP are
ranged between $0 to $100 per person per year, including
$16, the maximum drug price for which long-acting PrEP was
found to be potentially cost-effective. Non-drug related costs
are $66.91, see Table S5A. Time horizons range between one
to five years after full scale up. PrEP, pre-exposure prophy-
laxes
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